News | March 02, 2010

Leading Cardiologist Suggests Robotic System May Improve PCI Care

March 2, 2010 – A robotic cath lab navigation system may potentially raise the standard of care in percutaneous coronary intervention (PCI) by improving standardization, reproducibility and accuracy, according to George W. Vetrovec, M.D., of Virginia Commonwealth University Medical Center, when he spoke at CRT 2010 last week.

Corindus Vascular Robotics created a vascular robotic system designed to improve patient outcomes while protecting physicians from occupational hazards. Its CorPath vascular robotic system was the subject of a podium presentation last week at CRT.

“The CorPath vascular robotic system can potentially foster a new standard of care for precise stent deployment — which is a big challenge today due to the limited precision associated with manually controlled PCI procedures,” said Dr. Vetrovec, director of the adult cardiac catheterization laboratory, associate chairman of medicine for clinical affairs in the department of internal medicine, and a member of the VCU Health System Board of Directors. “My personal experience using the CorPath system leads me to believe that the system potentially offers interventional cardiologists and their patients several significant procedural advantages over the current manual PCI procedure.”

The CorPath system is designed to significantly reduce radiation exposure, physician fatigue and other occupational hazards to physicians by allowing him or her to operate in an ergonomically correct position while being shielded from harmful and repeated radiation exposure. Many doctors also face chronic orthopedic ailments and fatigue due to the required use of heavy lead protection garments.

Corindus designs, manufactures and commercializes precision vascular robotic systems for use in minimally invasive procedures. The company’s initial product, the CorPath system, is the world’s first to precisely drive coronary guide wires and stent/balloon catheters during PCI procedures performed in a cath lab. While Corindus is focused initially on PCIs, its open-platform technology and IP allow the Company to address other segments of the vascular market — including peripheral and other complex cardiac interventions such as structural heart disease repair.

The Corindus CorPath system is an investigational device in the United States and is limited by federal law to investigational use only.

For more information: www.corindus.com

Related Content

The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init